Menu
GWAS Study

Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy.

Hor H, Kutalik Z, Dauvilliers Y et al.

20711174 PubMed ID
GWAS Study Type
2129 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

HH
Hor H
KZ
Kutalik Z
DY
Dauvilliers Y
VA
Valsesia A
LG
Lammers GJ
DC
Donjacour CE
IA
Iranzo A
SJ
Santamaria J
PA
Peraita Adrados R
VJ
Vicario JL
OS
Overeem S
AI
Arnulf I
TI
Theodorou I
JP
Jennum P
KS
Knudsen S
BC
Bassetti C
MJ
Mathis J
LM
Lecendreux M
MG
Mayer G
GP
Geisler P
BA
Benetó A
PB
Petit B
PC
Pfister C
BJ
Bürki JV
DG
Didelot G
BM
Billiard M
EG
Ercilla G
VW
Verduijn W
CF
Claas FH
VP
Vollenweider P
WG
Waeber G
WD
Waterworth DM
MV
Mooser V
HR
Heinzer R
BJ
Beckmann JS
BS
Bergmann S
TM
Tafti M
Chapter II

Abstract

Summary of the research findings

Narcolepsy is a rare sleep disorder with the strongest human leukocyte antigen (HLA) association ever reported. Since the associated HLA-DRB1*1501-DQB1*0602 haplotype is common in the general population (15-25%), it has been suggested that it is almost necessary but not sufficient for developing narcolepsy. To further define the genetic basis of narcolepsy risk, we performed a genome-wide association study (GWAS) in 562 European individuals with narcolepsy (cases) and 702 ethnically matched controls, with independent replication in 370 cases and 495 controls, all heterozygous for DRB1*1501-DQB1*0602. We found association with a protective variant near HLA-DQA2 (rs2858884; P < 3 x 10(-8)). Further analysis revealed that rs2858884 is strongly linked to DRB1*03-DQB1*02 (P < 4 x 10(-43)) and DRB1*1301-DQB1*0603 (P < 3 x 10(-7)). Cases almost never carried a trans DRB1*1301-DQB1*0603 haplotype (odds ratio = 0.02; P < 6 x 10(-14)). This unexpected protective HLA haplotype suggests a virtually causal involvement of the HLA region in narcolepsy susceptibility.

562 European ancestry cases, 702 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

2129
Total Participants
GWAS
Study Type
Yes
Replicated
370 cases, 495 controls
Replication Participants
European
Ancestry
Italy, Netherlands, Spain, France, Denmark, Germany, Switzerland
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.